[Basel, Switzerland, April 23rd, 2025] – The global beta-blocker market, valued at 4.8 billion in 2023, is projected to grow at 5.2% to 7.2 billion by 2031, according to ClearView Market Insights. Innovations in extended-release formulations and transdermal delivery systems are transforming this essential drug class.
Request Sample @ https://clearviewmarketinsights.com/report-details/global-beta-adrenergic-receptor-antagonist-market/
2024 Key Advances
- Adherence Solutions: SmartPatch technology improves compliance to 92%
- Precision Medicine: Genetic testing guides optimal β-blocker selection
- Indication Expansion: PTSD and long COVID applications approved
Regional Leaders
- North America (XX%): High hypertension prevalence
- Europe (XX%): Strong generics market
- Asia-Pacific (XXX%): Rapid uptake in China/India
Executive Insight
"We're moving beyond one-size-fits-all β-blocker therapy to personalized solutions."
— Dr. Pascal Soriot, AstraZeneca CEO
Roadmap to 2031
- 2025: 50% of new Rx for extended-release formulations
- 2027: RNA-targeted β-blockers enter clinical use
- 2030: Digital therapeutics integration standard
For more insights, visit https://clearviewmarketinsights.com/report-store
About ClearView Market Insights
We analyze pharmaceutical markets with expertise in cardiovascular therapeutics.
Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369
